Business
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on
About this update from Aligos Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from December 3 – 7, 2023. The presentations can be found on the “Scientific Presentations & Conferences” section of the Aligos website (www.aligos.com). “We’re greatly encouraged by the substantial and consistent reductions in HBV viral markers observed during prolonged dosing of ALG-000184 and are grateful for the opportunity to share these results with the scientific community at the Hep-DART 2023 meeting,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics. “Consistent with the data that we recently presented at this year’s AASLD meeting, these promising results, including ALG-000184’s unique ability to affect cccDNA antigen expression, affirm our belief that it may have the potential to play a central role in enhancing rates of chronic suppression and/or functional cure in HBV.” Dr. Blatt continued: “We are also pleased for the opportunity to present findings from the Phase 1 trial of our THR-β agonist, ALG-055009, including favorable safety, lipid-lowering activity and differentiated pharmacology and pharmacokinetics, compared to competitor THR-β agonists. As presented at AASLD, ALG-055009 appears to have best-in-class potential. We look forward to the opportunity to demonstrate this promise for patients with NASH in the Phase 2a study, expected to begin in Q1 2024.” Presentation details: Title: Long-term Dosing with ALG-000184 in HBeAg Positive Subjects Results in Unprecedented Multi-log Reductions in HBV Markers Including HBsAg Presenter: Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics Key Highlights: Oral dosing with 300 mg of ALG-000184 ± entecavir (ETV) for up to 48 weeks in untreated HBeAg positive chronic hepatitis B patients demonstrated a favorable safety profile and greater suppression of HBV DNA and RNA versus ETV aloneNo viral breakthroughs occurred when ALG-000184 was given as a monotherapy...